Abstract
The guidelines provide specific recommendations based on published data or derived from expert consensus. Several analytes are found to have minimal clinical value at the present time, and measurement of them is not recommended.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e151-e199 |
| Journal | Diabetes care |
| Volume | 46 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2023 |
Funding
Acknowledgments. We are grateful to the following individuals who coauthored the original document on which these guidelines are based: David Goldstein, Noel Maclaren, Jay McDonald, and Marian Parrott. The authors thank Randie Little for insightful suggestions, ADA staff Malaika Hill, Laura Mitchell, and Mindy Saraco for expert help in compiling the document, and Jacqueline Weild for compiling the evidence tables. We also thank all those who submitted comments on preliminary drafts of the document. Funding. D.B.S., NIH Intramural Research Program. \u00C5.L., Swedish Research Council. Duality of Interest. D.B.S., Associate Editor for Clinical Chemistry, American Association for Clinical Chemistry, and Chair, Scientific Review Committee on Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. M.A.A., travel expenses paid by American Diabetes Association for attendance at the in-person manuscript review meeting, consulting for Rockley Photonics, a for-profit company working to develop wearable technology for fitness and wellness applications, including noninvasive glucose measurements, consulting for Foundation for Innovative New Diagnostics concerning the development of glucose sensing technologies for low-and middle-income countries, consulting for LifePlus concerning their interest in the development of a noninvasive glucose sensor for management of diabetes, and patent application filed (Olesberg, JT, Arnold, MA, Urea monitoring during dialysis for improved quality control and treatment guidance, U.S. Provisional Application 63/087,600 filed on 5 October 2020, International Patent Application No. PCT/US2021/053598 filed on 5 October 2021, U.S. Patent Application 18/ 030,339 filed on 5 April 2023). G.L.B., consultant or member of clinical trial steering committee for Bayer, KBP Biosciences, Ionis, Alnylam, AstraZeneca, Novo Nordisk, Janssen InREGEN and consulted for DiaMedica and Quantum Genomics. A.R.H., Elsev-ier, royalty for Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th edition, and Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, Chair of the Preanalytical glucose working party of the Australasian Association of Clinical Biochemistry and Laboratory Medicine, Chair of the Analytical Performance Specifications based on Outcomes Task Force Group of the European Federation of Clinical Chemistry and Laboratory Medicine. \u00C5.L., DiaMyd AB, Stockholm, Sweden, consulting fee. No other potential conflicts of interest relevant to this article were reported.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
